Not all fat is the same... where yours collects could signal an increased risk of an array of diseases

Obesity has long been known as a risk factor for a host of diseases like cancer and dementia, but researchers now say that ...
TipRanks on MSN

Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation for HER2+ CRC

Alphamab Oncology ( ($HK:9966) ) has issued an update. Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio ...
MedPage Today

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...
Targeted Oncology

Gedatolisib Improves PFS in PIK3CA-WT HR+/HER2– Breast Cancer

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Precision Medicine Online

Enhertu's Benefits in High-Risk Early-Stage Breast Cancer Come Into Focus in ESMO Data Readouts

The HER2-targeted ADC showed clear benefits over Roche's Kadcyla in the adjuvant setting, and promising activity versus standard neoadjuvant therapy.
Targeted Oncology

DESTINY-Breast11: Neoadjuvant T-DXd/THP Improves pCR in High-Risk HER2+ BC

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...
Le Lézard

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 ...